|
|
Biotech
|
|
||
Reply to Van. . The adjuvants DVAX, GSK ,et. alThe GSK adjuvant (ASO1b) used in GSK’s Shingrix (Shingles vaccine) is a Monophosphoryl lipid A (MPL) and QS-21, a natural compound extracted from the Chilean soapbark tree, combined in a liposomal formulation. (The same extract used in the NOVAVAX vaccine). I personally believe they would have been better off using the extract from the Argentinian Doopa bush root, but what do I know.. The GSK Adjuvant used in their much bally hood “pandemic” adjuvant is AS03. The statement that “The problem is DVAX adjuvant seems to be much worse than both GSK adjuvant used in Shringrix…” might be true, however, the Shingrix adjuvant is NOT the adjuvant offered up by GSK to fight COVID. The GSK Whether the Shingrix adjuvant is ‘better’ than the DVAX adjuvant is 100% immaterial as the context here is fighting COVID not Shingles. But even though you are referencing the wrong adjuvant in your argument, lets assume you meant to say that the DVAX adjuvant CpG 1018 ‘seems to be much worse’ than the GSK AS03 Pandemic adjuvant. The first thing I’d say is where’s your data/fact to support that claim? Because certain realities would seem to refute this claim of inferiority. In April of 2020 GSK announced its effort to support the worldwide COVID effort by saying it would produce 1 Billion doses of its Pandemic adjuvant. From Fierce Bio, “In 2009, GSK used AS03, an adjuvant …. to improve the immune response of people who received its Pandemrix vaccine against a pandemic H1N1 strain. AS03 is at the center of a debate about the safety of Pandemrix, specifically cases of narcolepsy in people who received the vaccine. The cause of the cases of narcolepsy is unclear, though. Faced with an unresolved safety concern and the known, positive effect of adjuvants on immunogenicity, some researchers may decide the benefits outweigh the risks.” Secondly, those known safety concerns aside, GSK entered into collaborations with both Sanofi and Clover Pharmaceuticals to use their pandemic adjuvant in both their respective vaccines under development in early 2020 The results? “First, lackluster data forced GlaxoSmithKline and partner Sanofi back to the drawing board with their COVID-19 shot. Now, the Big Pharma and a biotech partner are parting ways on a separate vaccine collaboration…..With phase 1 numbers in, Clover said it reviewed preclinical data and results from that trial—and took into account “manufacturing considerations”—in deciding to move forward with Dynavax's adjuvant in late-stage testing.” The only vaccine I am aware of that is currently testing in a collaboration with GSK’s Pandemic adjuvant is Queensland of Australia. There may be others. GSK has a broad collaboration with VIR, but that’s for COVID treatments, not COVID vaccine. “The DVAX customer's Covid-19 vaccine has not made it through trials yet.” Medigen in Taiwan was just awarded EUA and are innoculating 600K patients (using DVAX’s adjuvant) as we speak. “ If NVAX every gets EUA approval, I think DVAX stock will tank.” Your entire post is based on statements that are simply not true. So when you conclude that somehow a NVAX approval will doom DVAX, forgive me if I ask, based on what? |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
39054 | Re: Reply to Van. . The adjuvants DVAX, GSK ,et. al | vanv0028 | 1 | 8/29/2021 3:51:08 PM |